Transformative RNA-Based Treatments
-Antisense Oligonucleotides-
Targeting the Root Cause of Genetic Diseases
Our innovative RNA-based therapies, based on Antisense Oligonucleotides (ASOs) restore protein functionality, addressing untreatable genetic pulmonary illnesses.
Transformative RNA-Based Treatments
SpliSense is a company developing transformative RNA-based treatments for unmet needs relating to CF and other genetic pulmonary illnesses. Our treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation. We are focused on a variety of innovative therapies, in different development stages from discovery to IND .